
Barmer Collector Tina Dabi Visits TB Patient's Home, Delivers Nutrition Kit, Assures Support
Barmer TB Officer Dr. Arvind Kumar Bhatt said 1,200 patients are on treatment, and nutrition kits are being provided to them under the Nikshay Poshan Kit scheme
In a commendable act of empathy and leadership, Barmer District Collector Tina Dabi has set an example by directly assisting a TB patient. Under the 'Ni-Kshay Mitra' scheme, she handed over a nutrition kit to Motilal, a TB patient from Indira Colony, and assured him of the district administration's full support. This initiative falls under the Prime Minister's TB Free India Campaign, aiming to provide relief to TB patients.
In an effort spearheaded by the District Collector, other district-level officers, including the District Superintendent of Police, have also become Ni-Kshay Mitras, supporting a total of 69 TB patients in Barmer district.
On Wednesday, Dabi visited Motilal at his residence, providing him with the Nikshay Nutrition Kit and encouraging him to complete his treatment, promising all possible assistance.
According to Dr. Arvind Kumar Bhatt, Barmer's Tuberculosis Officer, 1,200 patients are currently undergoing TB treatment in the district. The Nikshay Poshan Kit scheme involves the distribution of nutrition kits to these patients.
Additionally, the Government of India provides a monthly allowance of Rs 1,000 to TB patients' accounts through Direct Benefit Transfer (DBT). As of 2025, a total of Rs 50 lakh has been paid out to patients via this scheme.
The nutrition kit, designed on the instructions of the District Collector, is nutrient-rich and includes 5 kg of millet, 1 kg of peanut seeds, 1 kg of moong dal, 1 kg of black gram, 1 kg of soybean gatta, 1 kg of soybean seeds, and 1 kg of soybean oil. The estimated cost of each kit is Rs 800.
First Published:
June 12, 2025, 19:29 IST
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
17 minutes ago
- Time of India
IDBI Bank Q1 Results: Standalone profit jumps 17% YoY to Rs 2,007 cr, NII drops 2%
IDBI Bank on Monday reported a 17% year-on-year (YoY) growth in its Q1FY26 standalone net profit at Rs 2,007 crore as compared to Rs 1,719 crore posted in the year-ago period. The private lender posted a Net Interest Income (NII) of Rs 3,166 crore in Q1 of FY26, which was 2% lower as against Rs 3,233 crore posted in Q1 of FY25. Explore courses from Top Institutes in Select a Course Category Healthcare MBA others Technology Others Digital Marketing Leadership CXO Data Science MCA Artificial Intelligence Project Management Data Science Management healthcare Degree Cybersecurity PGDM Public Policy Design Thinking Product Management Operations Management Finance Skills you'll gain: Financial Analysis in Healthcare Financial Management & Investing Strategic Management in Healthcare Process Design & Analysis Duration: 12 Weeks Indian School of Business Certificate Program in Healthcare Management Starts on Jun 13, 2024 Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Moose Approaches Girl At Bus Stop And Nudges Her To Follow - Watch What Happens Happy in Shape Undo MORE TO COME....


News18
an hour ago
- News18
MedGenome raises USD 47.5 mn in Series E funding round
New Delhi, Jul 21 (PTI) Genomic diagnostics and research services company MedGenome on Monday said it has raised USD 47.5 million (over Rs 409 crore) in Series E funding round from private equity firm Maj Invest and existing investor Novo Holdings. The round also saw participation from Sofina, an existing shareholder in the company, the Bengaluru-based firm said in a statement. The funding will enable the company to broaden access to its genomics and integrated diagnostics solutions across India and other emerging markets, it added. 'This fundraise also reflects the growing adoption of genomics in personalised and preventive healthcare in India as well as other emerging economies," MedGenome CEO Vedam Ramprasad said. MedGenome offers over 1,300 high-end genetic tests across major disease categories – oncology, inherited diseases, reproductive diseases, infectious diseases, and preventive wellness. PTI MSS MSS SHW Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.


Time of India
2 hours ago
- Time of India
ADIA to invest $200 million in Gujarat-based medtech co Meril
Ahmedabad: Abu Dhabi Investment Authority (ADIA) on Sunday announced it has signed definitive agreements to invest USD 200 million (approximately Rs 1,723 crore) in Gujarat-based medical devices manufacturer Meril, acquiring close to a 3% stake. The transaction values Meril at $6.6 billion (around Rs 56,859 crore). The deal awaits regulatory approval from the Competition Commission of India (CCI). The investment marks ADIA's latest play in India's expanding medical devices manufacturing space. Following the completion of the deal, Meril will be backed by two prominent global investors - ADIA and Warburg Pincus , which had earlier invested in the company. Founded by the Bilakhia Group, Meril is headquartered in Vapi, where it operates a 100-acre, vertically integrated MedTech campus powered entirely by green energy. The company develops and manufactures a range of clinically advanced products including cardiovascular devices, structural heart solutions, surgical robotics, orthopaedic implants, in-vitro diagnostics, and endo-surgery technologies. By far, Meril has invested Rs 1,400 crore in its Vapi facility. In Dec 2024, the company also inaugurated its new medical devices plant in Vapi. Meril exports its products to over 150 countries through a network of more than 35 subsidiaries. The company employs over 13,000 people globally and operates 12 international training academies, where it trains more than 10,000 healthcare professionals annually. tnn